At a glance
- Originator Eisai Co Ltd
- Class Antiarrhythmics; Ischaemic heart disorder therapies; Vasodilators
- Mechanism of Action Calcium channel antagonists; Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris; Arrhythmias
Most Recent Events
- 20 Mar 1997 Discontinued-Preclinical for Angina pectoris in Japan (Unknown route)
- 20 Mar 1997 Discontinued-Preclinical for Arrhythmias in Japan (Unknown route)